Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis.

Nieto LM, Martinez J, Narvaez SI, Ko D, Ko D, Kim DH, Vega KJ, Chawla S

The American journal of gastroenterology13 May 2025Cited by 17 (Europe PMC)

PMID40358430DOI10.14309/ajg.0000000000003525PepBankPUB-40358430

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study36

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone36

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less complicated pancreatitis than nonuse (HR 0.32).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less complicated pancreatitis than nonuse.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseComplicated pancreatitis
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Hazard ratio
0.32 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.14 to 0.74 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
The GLP-1 RAs group had lower risk of complicated pancreatitis (HR 0.32; 95% confidence interval [CI] 0.14-0.74)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4035843001
02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less complicated pancreatitis than nonuse (HR 0.32).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less complicated pancreatitis than nonuse.
Peptide
Liraglutide
Outcome
DecreaseComplicated pancreatitis
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Hazard ratio
0.32 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.14 to 0.74 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
The GLP-1 RAs group had lower risk of complicated pancreatitis (HR 0.32; 95% confidence interval [CI] 0.14-0.74)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4035843002
03HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less complicated pancreatitis than nonuse (HR 0.32).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less complicated pancreatitis than nonuse.
Peptide
Semaglutide
Outcome
DecreaseComplicated pancreatitis
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Hazard ratio
0.32 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.14 to 0.74 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
The GLP-1 RAs group had lower risk of complicated pancreatitis (HR 0.32; 95% confidence interval [CI] 0.14-0.74)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4035843003
04HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less complicated pancreatitis than nonuse (HR 0.32).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less complicated pancreatitis than nonuse.
Peptide
Tirzepatide
Outcome
DecreaseComplicated pancreatitis
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Hazard ratio
0.32 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.14 to 0.74 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
The GLP-1 RAs group had lower risk of complicated pancreatitis (HR 0.32; 95% confidence interval [CI] 0.14-0.74)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4035843004
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less parenteral nutrition than nonuse (HR 0.28).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less parenteral nutrition than nonuse.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseParenteral nutrition need
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Hazard ratio
0.28 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.09 to 0.83 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
parenteral nutrition needs (HR 0.28; 95% CI 0.09-0.83)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4035843005
06HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less parenteral nutrition than nonuse (HR 0.28).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less parenteral nutrition than nonuse.
Peptide
Liraglutide
Outcome
DecreaseParenteral nutrition need
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Hazard ratio
0.28 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.09 to 0.83 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
parenteral nutrition needs (HR 0.28; 95% CI 0.09-0.83)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4035843006
07HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less parenteral nutrition than nonuse (HR 0.28).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less parenteral nutrition than nonuse.
Peptide
Semaglutide
Outcome
DecreaseParenteral nutrition need
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Hazard ratio
0.28 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.09 to 0.83 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
parenteral nutrition needs (HR 0.28; 95% CI 0.09-0.83)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4035843007
08HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less parenteral nutrition than nonuse (HR 0.28).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less parenteral nutrition than nonuse.
Peptide
Tirzepatide
Outcome
DecreaseParenteral nutrition need
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Hazard ratio
0.28 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.09 to 0.83 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
parenteral nutrition needs (HR 0.28; 95% CI 0.09-0.83)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4035843008
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less sepsis than nonuse (HR 0.71).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less sepsis than nonuse.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseSepsis
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Infection and antimicrobial activity · Infection
Measurements
Hazard ratio
0.71 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.59 to 0.84 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
sepsis (HR 0.71; 95% CI 0.59-0.84)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4035843009
10HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less sepsis than nonuse (HR 0.71).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less sepsis than nonuse.
Peptide
Liraglutide
Outcome
DecreaseSepsis
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Infection and antimicrobial activity · Infection
Measurements
Hazard ratio
0.71 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.59 to 0.84 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
sepsis (HR 0.71; 95% CI 0.59-0.84)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4035843010
11HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less sepsis than nonuse (HR 0.71).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less sepsis than nonuse.
Peptide
Semaglutide
Outcome
DecreaseSepsis
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Infection and antimicrobial activity · Infection
Measurements
Hazard ratio
0.71 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.59 to 0.84 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
sepsis (HR 0.71; 95% CI 0.59-0.84)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4035843011
12HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less sepsis than nonuse (HR 0.71).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less sepsis than nonuse.
Peptide
Tirzepatide
Outcome
DecreaseSepsis
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Infection and antimicrobial activity · Infection
Measurements
Hazard ratio
0.71 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.59 to 0.84 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
sepsis (HR 0.71; 95% CI 0.59-0.84)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4035843012
13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less acute kidney injury than nonuse (HR 0.54).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less acute kidney injury than nonuse.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAcute kidney injury
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Measurements
Hazard ratio
0.54 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.49 to 0.6 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
acute kidney injury (HR 0.54; 95% CI 0.49-0.60)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4035843013
14HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less acute kidney injury than nonuse (HR 0.54).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less acute kidney injury than nonuse.
Peptide
Liraglutide
Outcome
DecreaseAcute kidney injury
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Measurements
Hazard ratio
0.54 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.49 to 0.6 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
acute kidney injury (HR 0.54; 95% CI 0.49-0.60)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4035843014
15HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less acute kidney injury than nonuse (HR 0.54).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less acute kidney injury than nonuse.
Peptide
Semaglutide
Outcome
DecreaseAcute kidney injury
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Measurements
Hazard ratio
0.54 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.49 to 0.6 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
acute kidney injury (HR 0.54; 95% CI 0.49-0.60)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4035843015
16HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less acute kidney injury than nonuse (HR 0.54).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less acute kidney injury than nonuse.
Peptide
Tirzepatide
Outcome
DecreaseAcute kidney injury
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Measurements
Hazard ratio
0.54 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.49 to 0.6 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
acute kidney injury (HR 0.54; 95% CI 0.49-0.60)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4035843016
17HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less shock than nonuse (HR 0.52).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less shock than nonuse.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseShock
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Hazard ratio
0.52 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.36 to 0.75 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
shock (HR 0.52; 95% CI 0.36-0.75)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4035843017
18HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less shock than nonuse (HR 0.52).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less shock than nonuse.
Peptide
Liraglutide
Outcome
DecreaseShock
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Hazard ratio
0.52 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.36 to 0.75 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
shock (HR 0.52; 95% CI 0.36-0.75)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4035843018
19HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less shock than nonuse (HR 0.52).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less shock than nonuse.
Peptide
Semaglutide
Outcome
DecreaseShock
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Hazard ratio
0.52 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.36 to 0.75 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
shock (HR 0.52; 95% CI 0.36-0.75)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4035843019
20HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less shock than nonuse (HR 0.52).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less shock than nonuse.
Peptide
Tirzepatide
Outcome
DecreaseShock
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Hazard ratio
0.52 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.36 to 0.75 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
shock (HR 0.52; 95% CI 0.36-0.75)
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4035843020
21HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less mechanical ventilation than nonuse (HR 0.23).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less mechanical ventilation than nonuse.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseMechanical ventilation
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Respiratory function · Respiratory
Measurements
Hazard ratio
0.23 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.16 to 0.33 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
and mechanical ventilation support during admission (HR 0.23; 95% CI 0.16-0.33) compared with the non-GLP-1 RAs group.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4035843021
22HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less mechanical ventilation than nonuse (HR 0.23).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less mechanical ventilation than nonuse.
Peptide
Liraglutide
Outcome
DecreaseMechanical ventilation
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Respiratory function · Respiratory
Measurements
Hazard ratio
0.23 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.16 to 0.33 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
and mechanical ventilation support during admission (HR 0.23; 95% CI 0.16-0.33) compared with the non-GLP-1 RAs group.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4035843022
23HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less mechanical ventilation than nonuse (HR 0.23).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less mechanical ventilation than nonuse.
Peptide
Semaglutide
Outcome
DecreaseMechanical ventilation
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Respiratory function · Respiratory
Measurements
Hazard ratio
0.23 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.16 to 0.33 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
and mechanical ventilation support during admission (HR 0.23; 95% CI 0.16-0.33) compared with the non-GLP-1 RAs group.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4035843023
24HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to less mechanical ventilation than nonuse (HR 0.23).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to less mechanical ventilation than nonuse.
Peptide
Tirzepatide
Outcome
DecreaseMechanical ventilation
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Respiratory function · Respiratory
Measurements
Hazard ratio
0.23 HR
GLP-1 receptor agonist users versus matched non-users
95% confidence interval of hazard ratio
0.16 to 0.33 HR
GLP-1 receptor agonist users versus matched non-users
Source sentences
Summary
and mechanical ventilation support during admission (HR 0.23; 95% CI 0.16-0.33) compared with the non-GLP-1 RAs group.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4035843024
25HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use showed no significant difference in uncomplicated pancreatitis versus nonuse (HR 0.71).
In plain wordsIn patients with diabetes, uncomplicated pancreatitis did not differ significantly between pooled GLP-1 drug users and nonusers.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeUncomplicated pancreatitis
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
HR
0.71 ratio
GLP-1 RA group vs non-GLP-1 RA group, uncomplicated pancreatitis
95% CI
0.49 to 1.01 ratio
GLP-1 RA group vs non-GLP-1 RA group, uncomplicated pancreatitis
Source sentences
Summary
Important to note that the GLP-1 RAs group had a tendency of lower risk of uncomplicated pancreatitis (HR 0.71; 95% CI 0.49-1.01) but without statistically significant result.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4035843029
26HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use showed no significant difference in uncomplicated pancreatitis versus nonuse (HR 0.71).
In plain wordsIn patients with diabetes, uncomplicated pancreatitis did not differ significantly between pooled GLP-1 drug users and nonusers.
Peptide
Liraglutide
Outcome
No significant changeUncomplicated pancreatitis
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
HR
0.71 ratio
GLP-1 RA group vs non-GLP-1 RA group, uncomplicated pancreatitis
95% CI
0.49 to 1.01 ratio
GLP-1 RA group vs non-GLP-1 RA group, uncomplicated pancreatitis
Source sentences
Summary
Important to note that the GLP-1 RAs group had a tendency of lower risk of uncomplicated pancreatitis (HR 0.71; 95% CI 0.49-1.01) but without statistically significant result.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4035843030
27HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use showed no significant difference in uncomplicated pancreatitis versus nonuse (HR 0.71).
In plain wordsIn patients with diabetes, uncomplicated pancreatitis did not differ significantly between pooled GLP-1 drug users and nonusers.
Peptide
Semaglutide
Outcome
No significant changeUncomplicated pancreatitis
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
HR
0.71 ratio
GLP-1 RA group vs non-GLP-1 RA group, uncomplicated pancreatitis
95% CI
0.49 to 1.01 ratio
GLP-1 RA group vs non-GLP-1 RA group, uncomplicated pancreatitis
Source sentences
Summary
Important to note that the GLP-1 RAs group had a tendency of lower risk of uncomplicated pancreatitis (HR 0.71; 95% CI 0.49-1.01) but without statistically significant result.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4035843031
28HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use showed no significant difference in uncomplicated pancreatitis versus nonuse (HR 0.71).
In plain wordsIn patients with diabetes, uncomplicated pancreatitis did not differ significantly between pooled GLP-1 drug users and nonusers.
Peptide
Tirzepatide
Outcome
No significant changeUncomplicated pancreatitis
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
HR
0.71 ratio
GLP-1 RA group vs non-GLP-1 RA group, uncomplicated pancreatitis
95% CI
0.49 to 1.01 ratio
GLP-1 RA group vs non-GLP-1 RA group, uncomplicated pancreatitis
Source sentences
Summary
Important to note that the GLP-1 RAs group had a tendency of lower risk of uncomplicated pancreatitis (HR 0.71; 95% CI 0.49-1.01) but without statistically significant result.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4035843032
29HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with diabetes, systemic inflammatory response syndrome risk did not differ between pooled GLP-1 drug users and nonusers.
In plain wordsIn patients with diabetes, systemic inflammatory response syndrome risk did not differ between pooled GLP-1 drug users and nonusers.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeSystemic inflammatory response syndrome
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
No difference was found between the groups in risk of developing systemic inflammatory response syndrome if it occurs.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4035843033
30HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with diabetes, systemic inflammatory response syndrome risk did not differ between pooled GLP-1 drug users and nonusers.
In plain wordsIn patients with diabetes, systemic inflammatory response syndrome risk did not differ between pooled GLP-1 drug users and nonusers.
Peptide
Liraglutide
Outcome
No significant changeSystemic inflammatory response syndrome
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
No difference was found between the groups in risk of developing systemic inflammatory response syndrome if it occurs.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4035843034
31HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with diabetes, systemic inflammatory response syndrome risk did not differ between pooled GLP-1 drug users and nonusers.
In plain wordsIn patients with diabetes, systemic inflammatory response syndrome risk did not differ between pooled GLP-1 drug users and nonusers.
Peptide
Semaglutide
Outcome
No significant changeSystemic inflammatory response syndrome
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
No difference was found between the groups in risk of developing systemic inflammatory response syndrome if it occurs.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4035843035
32HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In patients with diabetes, systemic inflammatory response syndrome risk did not differ between pooled GLP-1 drug users and nonusers.
In plain wordsIn patients with diabetes, systemic inflammatory response syndrome risk did not differ between pooled GLP-1 drug users and nonusers.
Peptide
Tirzepatide
Outcome
No significant changeSystemic inflammatory response syndrome
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Primary
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
No difference was found between the groups in risk of developing systemic inflammatory response syndrome if it occurs.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4035843036
33HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to lower mortality than nonuse (HR 0.45).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to fewer deaths than nonuse.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAll-cause mortality
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Secondary
Outcome group
Mortality · Whole body
Measurements
HR
0.45 ratio
GLP-1 RA group vs non-GLP-1 RA group, all-cause mortality
95% CI
0.41 to 0.49 ratio
GLP-1 RA group vs non-GLP-1 RA group, all-cause mortality
Source sentences
Summary
In addition, all-cause mortality was decreased in the GLP-1 agonist group compared with the non-GLP-1 agonist group (HR 0.45; 95% CI 0.41-0.49).
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4035843025
34HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to lower mortality than nonuse (HR 0.45).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to fewer deaths than nonuse.
Peptide
Liraglutide
Outcome
DecreaseAll-cause mortality
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Secondary
Outcome group
Mortality · Whole body
Measurements
HR
0.45 ratio
GLP-1 RA group vs non-GLP-1 RA group, all-cause mortality
95% CI
0.41 to 0.49 ratio
GLP-1 RA group vs non-GLP-1 RA group, all-cause mortality
Source sentences
Summary
In addition, all-cause mortality was decreased in the GLP-1 agonist group compared with the non-GLP-1 agonist group (HR 0.45; 95% CI 0.41-0.49).
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4035843026
35HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to lower mortality than nonuse (HR 0.45).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to fewer deaths than nonuse.
Peptide
Semaglutide
Outcome
DecreaseAll-cause mortality
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Secondary
Outcome group
Mortality · Whole body
Measurements
HR
0.45 ratio
GLP-1 RA group vs non-GLP-1 RA group, all-cause mortality
95% CI
0.41 to 0.49 ratio
GLP-1 RA group vs non-GLP-1 RA group, all-cause mortality
Source sentences
Summary
In addition, all-cause mortality was decreased in the GLP-1 agonist group compared with the non-GLP-1 agonist group (HR 0.45; 95% CI 0.41-0.49).
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4035843027
36HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In patients with diabetes, pooled GLP-1 drug use was linked to lower mortality than nonuse (HR 0.45).
In plain wordsIn patients with diabetes, pooled GLP-1 drug use was linked to fewer deaths than nonuse.
Peptide
Tirzepatide
Outcome
DecreaseAll-cause mortality
Study
n: not reported in source
Comparator
No GLP-1 receptor agonist use
Analysis
Secondary
Outcome group
Mortality · Whole body
Measurements
HR
0.45 ratio
GLP-1 RA group vs non-GLP-1 RA group, all-cause mortality
95% CI
0.41 to 0.49 ratio
GLP-1 RA group vs non-GLP-1 RA group, all-cause mortality
Source sentences
Summary
In addition, all-cause mortality was decreased in the GLP-1 agonist group compared with the non-GLP-1 agonist group (HR 0.45; 95% CI 0.41-0.49).
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed using population-based data from the TriNetX platform.
Summary · context
Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included.
Summary · context
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4035843028

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 5Current
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 4
21 Oct 2026, 18:59 UTC
The same notice was added 3 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.